Skip to main content
Clinical Trials/IRCT20100520003979N9
IRCT20100520003979N9
Recruiting
Phase 2

The evaluation of atypical antipsychotic augmentation with Atomoxetine in the reduction of negative symptoms in patients with Schizophrenia

Ahvaz University of Medical Sciences0 sites60 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Schizophrenia.
Sponsor
Ahvaz University of Medical Sciences
Enrollment
60
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Detection of schizophrenia based on the diagnosis of a faculty psychiatrist and an psychiatrist assistant with a clinical interview based on DSM\-5
  • Bold negative symptoms( PANSS negative symptom sub\-scale score more than 15\)
  • Not having liver disease
  • Suffering from the disease for more than a year
  • Age between 18 and 70 years.

Exclusion Criteria

  • Presence of Depression based on DSM\-5 Clinical Interview
  • Presence of Bipolar disorder
  • Pregnant or lactating woman
  • Substance abuse during the last month
  • patients suffering from Attention Deficit Hyperactivity Disorder (ADHD)

Outcomes

Primary Outcomes

Not specified

Similar Trials